axitinib Archives - Kidney Cancer Support Network

Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland

The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the avelumab plus axitinib combination for untreated advanced kidney cancer for patients in Scotland. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for avelumab in combination with axitinib for the first-line treatment of patients with advanced or metastatic renal cell carcinoma […]

Oct 12, 2020 / Comments Off / Sharon Kell / Tags: avelumab, axitinib, Bavencio, combination therapy, immunotherapy, Inlyta, progression-free survival, renal cell carcinoma, TKIs, VEGF inhibitors

Biological markers of response for kidney cancer

To date, a reliable biomarker is yet to be discovered for the response of kidney cancer patients to treatment or for prognosis. In this review paper, Dr Robert Motzer and his research group from Memorial Sloan Kettering in the USA identified a set of 26 genes whose activity correlated with progression-free survival in the combination […]

Sep 10, 2020 / Comments Off / Sharon Kell / Tags: avelumab, axitinib, Bavencio, biomarkers, genetic testing, Inlyta, renal cell carcinoma, sunitinib, Sutent

Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer

The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for pemrolizumab in combination with axitinib for untreated patients with advanced or metastatic renal cell […]

Sep 07, 2020 / Comments Off / Sharon Kell / Tags: axitinib, combination therapy, Inlyta, Keytruda, pembrolizumab, renal cell carcinoma, SMC

Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer

The National Institute for Health and Care Excellence (NICE) have issued a final decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Final Appraisal Document (FAD) released today, NICE stated that there was uncertainty about the long-term benefits of the pembrolizumab plus axitinib […]

Aug 27, 2020 / Comments Off / Sharon Kell / Tags: axitinib, combination therapy, first-line treatment, Inlyta, Keytruda, NICE, pembrolizumab, renal cell carcinoma

Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer

KCSN are formal consultants to NICE and part of the process that appraises all new kidney cancer drugs. We are delighted to tell you that, as from today, kidney cancer patients can get NHS funding via the Cancer Drugs Fund for avelumab in combination with axitinib as a first-line treatment for patients with untreated advanced […]

Jul 31, 2020 / Comments Off / Julia / Tags: avelumab, axitinib, Bavencio, first-line treatment, health technology appraisal, Inlyta, metastases, NICE, renal cell carcinoma

ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer

Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program over the weekend. The combination of pembrolizumab with axitinib continues to show improved efficacy in the treatment of advanced RCC […]

Jun 01, 2020 / Comments Off / Sharon Kell / Tags: ASCO, axitinib, combination therapy, Inlyta, Keytruda, overall survival, pembrolizumab, progression-free survival, renal cell carcinoma

Axitinib effective as a third-line treatment for kidney cancer

A recent study published in the journal In Vivo assessed the therapeutic effect of axitinib as a third-line therapy following second-line nivolumab monotherapy in patients with metastatic renal cell carcinoma (RCC). Data from patients treated with axitinib as a third-line therapy after failure of first-line tyrosine kinase inhibitor (TKI) and second-line nivolumab monotherapy were reviewed. […]

May 19, 2020 / Comments Off / Sharon Kell / Tags: axitinib, Inlyta, metastases, renal cell carcinoma, third-line treatment

Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer

Data from a recent phase I study of seleno-L-methionine in combination with axitinib (Inlyta) as treatment for patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC) were presented at the American Urological Association (AUA) Virtual Experience meeting over the weekend. There were 15 patients in the study with ccRCC whose disease had […]

May 18, 2020 / Comments Off / Sharon Kell / Tags: axitinib, Inlyta, renal cell carcinoma, response rate, seleno-L-methionine, treatments response

Axitinib first-line treatment of papillary renal cell carcinoma

The majority of renal cell carcinomas (RCCs) are a subtype called clear cell RCC. Most drugs have been developed to treat this subtype of RCC, leaving people with other metastatic RCC subtypes with an unmet need for an effective treatment in the first-line. Papillary RCC (pRCC) represents 10-15% of renal cell carcinomas, and is not an insignificant subtype. […]

Mar 17, 2020 / Comments Off / Sharon Kell / Tags: axitinib, Inlyta, non-clear cell kidney cancer, objective response, overall survival, papillary RCC, progression-free survival

Individualised axitinib dosing for patients with metastatic kidney cancer

In the following video interview with Practice Update, Dr Nancy Davis from Vanderbilt University Medical Center in Nashville, Tennessee, USA talks about a study looking at individualised dosing of axitinib for patients with metastatic renal cell carcinoma (RCC) based on toxicity. This was a single-arm study in patients with metastatic predominately clear cell RCC who […]

Mar 09, 2020 / Comments Off / Sharon Kell / Tags: axitinib, individualised treatment, Inlyta, renal cell carcinoma

Showing 1 to 10 of 63 results

TOP

Settings

Shopping Bag